A high neutrophil-lymphocyte ratio and platelet-lymphocyte ratio are associated with a worse outcome in inflammatory breast cancer von Van Berckelaer, C., Van Geyt, M., Linders, S., Rypens, C., Trinh, X.B., Tjalma, W.A.A., Van Laere, S., Colpaert, C., Dirix, L., van Dam, P.A.

Volltext

Is there a role for urokinase-type plasminogen activator inhibitors as maintenance therapy in patients with ovarian cancer? von van Dam, P.A, Coelho, A, Rolfo, C

Volltext

Neoadjuvant endocrine treatment in early breast cancer: An overlooked alternative? von van Dam, P.A, van Dam, V.C.N, Altintas, S, Papadimitriou, K, Rolfo, C, Trinh, X.B

Volltext

The effect of EUSOMA certification on quality of breast cancer care von van Dam, P.A, Tomatis, M, Marotti, L, Heil, J, Wilson, R, Rosselli del Turco, M, Mayr, C, Costa, A, Danei, M, Denk, A, Emons, G, Friedrichs, K, Harbeck, N, Kiechle, M, Koheler, U, Kuemmel, S, Maass, N, Marth, C, Prové, A, Kimmig, R, Rageth, C, Regolo, L, Salehi, L, Sarlos, D, Singer, C, Sohn, C, Staelens, G, Tinterri, C, Ponti, A

Volltext

The role of macrophages in hormone positive breast cancer von Oner, G., Van Berckelaer, C., Praet, M., Canturk, N.Z., Altintas, S., Tjalma, W., Zwi, B., Peters, M., Pauwels, P., van Dam, P.A.

Volltext

Inflammatory response to neoadjuvant endocrine therapy in hormone receptor-positive breast cancer von Oner, G., Van Berckelaer, C., Praet, M., Canturk, N.Z., Altintas, S., Tjalma, W., Berneman, Z., Peeters, M., Pauwels, P., van Dam, P.A.

Volltext

2166P Long-term consequences of SARS-CoV-2 infection in cancer patients von Debie, Y., Palte, Z., Salman, H., Verbruggen, L., Vanhoutte, G., Raats, S., Roelant, E., Vandamme, T., Peeters, M., van Dam, P.A.

Volltext

1780TiP Ambulatory follow-up care and monitoring of cancer patients during SARS-CoV-2 pandemic by collecting blood samples at home and monitoring systemic therapy using a smartphon... von Peeters, M., Vulsteke, C., Rasschaert, M., Ravelingien, J., Van Vooren, P., Vanhoutte, G., De Backer, L., van Dam, P.A.

Volltext

Time trends (2006–2015) of quality indicators in EUSOMA-certified breast centres von van Dam, P.A., Tomatis, M., Marotti, L., Heil, J., Mansel, R.E., Rosselli del Turco, M., van Dam, P.J., Casella, D., Bassani, L.G., Danei, M., Denk, A., Egle, D., Emons, G., Friedrichs, K., Harbeck, N., Kiechle, M., Kimmig, R., Koehler, U., Kuemmel, S., Maass, N., Mayr, C., Prové, A., Rageth, C., Regolo, L., Lorenz-Salehi, F., Sarlos, D., Singer, C., Sohn, C., Staelens, G., Tinterri, C., Audisio, R., Ponti, A., Badbanchi, F., Catalano, G., Cretella, E., Daniaux, M., Emons, A., van Eygen, K., Ettl, J., Gatzemeier, W., Kern, P., Schneeweiss, A., Stoeblen, F., Van As, A., Wuerstlein, R., Zanini, V.

Volltext

1666P Lower virus neutralizing titers against SARS-CoV-2 Omicron strain after third dose BNT162b2 following primo-vaccination with ChAdOx1 versus BNT162b2 in cancer patients von Debie, Y., Van Audenaerde, J., Vandamme, T., Croes, L., Teuwen, L-A.M.N., Verbruggen, L., Vanhoutte, G., Marcq, E., Le Blon, D., Peeters, B., M.E. Goossens, Arien, K., Anguille, S., Smits, E., Vulsteke, C., Lion, E., Peeters, M., van Dam, P.A.

Volltext

Bevacizumab in the treatment of patients with advanced breast cancer: where have we landed? von Dirix, L.Y., Van Dam, P.A., Prove, A.M., Vermeulen, P.B.

Volltext

159P Pembrolizumab, SBRT, and immunomodulation for recurrent and/or refractory cervical or endometrial carcinoma von De Jaeghere, E.A., Tuyaerts, S., Van Nuffel, A.M.T., Lippens, L., Hendrix, A., Vuylsteke, P., Henry, S., Trinh, X.B., Van Dam, P.A., Aspeslagh, S., De Caluwe, A., Naert, E., Van de Vijver, K., Amant, F., Vandecasteele, K., Denys, H.G.

Volltext

Current and future role of circulating tumor cells in patients with epithelial ovarian cancer von Van Berckelaer, C., Brouwers, A.J., Peeters, D.J.E., Tjalma, W., Trinh, X.B., van Dam, P.A.

Volltext

273P Expression2Kinases (E2K) analysis indentifies potential drugable kinases for targeted treatment of cervical carcinoma von van Dam, P.A., van Dam, P.-J., Rolfo, C.D., Trinh, X.B., Altintas, S., Huizing, M.T., Papadimitriou, K., Tjalma, W., van Laere, S.

Volltext

Review: Current and future role of circulating tumor cells in patients with epithelial ovarian cancer von Van Berckelaer, C, Brouwers, A.J, Peeters, D.J.E, Tjalma, W, Trinh, X.B, van Dam, P.A

Volltext

Comparison of S1 antibody titers between BNT162b2 and ChAdOx1 COVID-19 vaccination in cancer patients von van Dam, P.A., Debie, Y., Teuwen, L., Verbruggen, L., Vanhoutte, G., Peeters, B., Croes, L., Vulsteke, C., Anguille, S., Vandamme, T., Peeters, M.

Volltext

5007 ORAL Correlation of the AKT/mTOR/p70S6K1 pathway and phosphorylated vascular endothelial growth factor receptor 2 in human epithelial ovarian cancer von Trinh, X.B, Tjalma, W.A.A, Dirix, L.Y, Vemeulen, P.B, van Den Eynden, G.G, van Laere, S.J, van Der Auwera, I, van Dam, P.A

Volltext

Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I–II trial von van Driel, W.J., Ressing, M.E., Kenter, G.G., Brandt, R.M.P., Krul, E.J.T., van Rossum, A.B., Schuuring, E., Offringa, R., Bauknecht, T., Tamm-Hermelink, A., van Dam, P.A., Fleuren, G.J., Kast, W.M., Melief, C.J.M., Trimbos, J.B.

Volltext

A cross-sectional, multicentre, epidemiological study on human papillomavirus (HPV) type distribution in adult women diagnosed with invasive cervical cancer in Belgium von Tjalma, W A A, Trinh, X B, Rosenlund, M, Makar, A P, Kridelka, F, Rosillon, D, Van Dam, P A, Collas De Souza, S, Holl, K, Simon, P, Jenkins, D

Volltext

The socio-economical impact of intravenous (IV) versus subcutaneous (SC) administration of trastuzumab: future prospectives von Papadmitriou, K, Trinh, X B, Altintas, S, Van Dam, P A, Huizing, M T, Tjalma, W A A

Volltext